Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2411.68% is 96% above its 1-year average of -54092.90%, near the high end of its 1-year range (-262900.00%–-371.25%).
96.17% above its 12-month average of -62955.40%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2024 (2024-12-31): -262900.00%.
EBITDA MARGIN
-2411.68%
EBITDA MARGIN AVG TTM
-62955.40%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+96.17%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ernexa Therapeutics Inc.
Market Cap
$4.41M
EBITDA Margin
-2411.68%
TTM Avg
-62955.40%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.42M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$4.32M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
Market Cap
$4.58M
EBITDA Margin
-1670.57%
TTM Avg
-1446.66%
3Y Avg
-2067.25%
5Y Avg
-1679.39%
Market Cap
$4.18M
EBITDA Margin
-1456.00%
TTM Avg
-1456.00%
3Y Avg
-1456.00%
5Y Avg
-1456.00%
Market Cap
$4.79M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$3.94M
EBITDA Margin
-890.82%
TTM Avg
-527.81%
3Y Avg
-554.45%
5Y Avg
-445.87%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $4.41M | -2411.68% | -62955.40% | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -159.06% | -237.19% | -222.87% | -159.05% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.58M | -1670.57% | -1446.66% | -2067.25% | -1679.39% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | -890.82% | -527.81% | -554.45% | -445.87% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | -8.85% | 9.13% | 18.32% | 18.32% |
Gross Margin
0.0%
EBITDA Margin
-2411.7%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-12-31 | -262900.00% |
| 2024-09-30 | -371.25% |
| 2024-06-30 | -9261.70% |
| 2024-03-31 | -11161.70% |
| 2023-12-31 | -31082.35% |
| 2023-09-30 | -9780.39% |
